Levetiracetam (UCB-L059)

Synonyms: UCB-L059, SIB-S1

Levetiracetam (UCB-L059, SIB-S1) is an anticonvulsant medication used to treat epilepsy. Levetiracetam (UCB-L059, SIB-S1) is an agonist of muscarinic acetylcholine receptors (mAChR). Levetiracetam modulates the presynaptic P/Q-type voltage-dependent calcium (Ca2+) channel.

Levetiracetam (UCB-L059) Chemical Structure

Levetiracetam (UCB-L059) Chemical Structure

CAS No. 102767-28-2

Purity & Quality Control

Levetiracetam (UCB-L059) Related Products

Biological Activity

Description Levetiracetam (UCB-L059, SIB-S1) is an anticonvulsant medication used to treat epilepsy. Levetiracetam (UCB-L059, SIB-S1) is an agonist of muscarinic acetylcholine receptors (mAChR). Levetiracetam modulates the presynaptic P/Q-type voltage-dependent calcium (Ca2+) channel.
Targets
Calcium channel [1]
In vitro
In vitro Levetiracetam and related compounds bind to SV2A expressed in fibroblasts, indicating that SV2A is sufficient for Levetiracetam binding. [1] Levetiracetam irreversibly inhibits the high-voltage-activated (HVA) calcium current by approximately 18% on the average in freshly isolated CA1 hippocampal neurons of rats. Levetiracetam selectively inhibits N-type Ca2+ channels of CA1 pyramidal hippocampal neurons. [2] Levetiracetam reverses the inhibitory effect of DMCM on GABA-elicited currents in hippocampal neurons. [3]
In Vivo
In vivo Levetiracetam (17 mg/kg) produces a potent suppression of sound-induced clonic convulsions in mice, and this protective effect is significantly abolished by co-administration of the beta-carboline FG 7142. [3] Levetiracetam exerts potent anticonvulsant activity against both focal and secondarily generalized seizures in fully amygdala-kindled rats, i.e. , a model of temporal lobe epilepsy. Levetiracetam (13 mg/kg, 27 mg/kg or 54 mg/kg, i.p.) dose-dependently suppresses the increase in seizure severity and duration induced by repeated amygdala stimulation. Levetiracetam has a relatively short half-life (about 2-3 hours) in rats. [4] Levetiracetam (5.4 mg/kg to 96 mg/kg i.p.) dose-dependently inhibits both wild running and tonic-clonic convulsions in the audiogenic-seizure prone rat. Levetiracetam markedly suppresses spontaneous spike-and-wave discharge (SWD) but leaves the underlying EEG trace normal in the GAERS model of petit mal epilepsy. [5]
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT05860153 Not yet recruiting
Febrile Convulsion
Assiut University
June 1 2023 Not Applicable
NCT06403150 Enrolling by invitation
Status Epilepticus
Dhaka Medical College
May 15 2023 Phase 4
NCT06067412 Completed
Status Epilepticus
Shaheed Zulfiqar Ali Bhutto Medical University
August 1 2022 Not Applicable
NCT04425798 Unknown status
Glioma|Epilepsy
Beijing Neurosurgical Institute|Beijing Tiantan Hospital
May 25 2022 --
NCT04117425 Recruiting
Epilepsy in Pregnancy
Assistance Publique - Hôpitaux de Paris
April 20 2022 Not Applicable

Chemical Information & Solubility

Molecular Weight 170.21 Formula

C8H14N2O2

CAS No. 102767-28-2 SDF Download Levetiracetam (UCB-L059) SDF
Smiles CCC(C(=O)N)N1CCCC1=O
Storage (From the date of receipt)

In vitro
Batch:

DMSO : 34 mg/mL ( (199.75 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Water : 34 mg/mL

Ethanol : 34 mg/mL


Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.


In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Levetiracetam (UCB-L059) | Levetiracetam (UCB-L059) ic50 | Levetiracetam (UCB-L059) price | Levetiracetam (UCB-L059) cost | Levetiracetam (UCB-L059) solubility dmso | Levetiracetam (UCB-L059) purchase | Levetiracetam (UCB-L059) manufacturer | Levetiracetam (UCB-L059) research buy | Levetiracetam (UCB-L059) order | Levetiracetam (UCB-L059) mouse | Levetiracetam (UCB-L059) chemical structure | Levetiracetam (UCB-L059) mw | Levetiracetam (UCB-L059) molecular weight | Levetiracetam (UCB-L059) datasheet | Levetiracetam (UCB-L059) supplier | Levetiracetam (UCB-L059) in vitro | Levetiracetam (UCB-L059) cell line | Levetiracetam (UCB-L059) concentration | Levetiracetam (UCB-L059) nmr